Gilead Sciences Inc
NASDAQ: GILD
$68.65
+$0.53 (+0.8%)
Closing price April 11, 2024
These seven stocks combined can generate about $3,750 a year in passive income for an investment of just $7,500 in each one.
Published:
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
Published:
Fourth-quarter earnings kick off in a big way in 7 to 10 days, and earnings at some of the biggest and best U.S. companies are likely expected to decline for the third quarter running. Many top...
Published:
While many investment professionals suggest short Treasury paper and money markets, healthcare is the place in 2024 for long-term investors looking for growth and income. Demand is growing as the...
Published:
This year’s Artificial Intelligence rally led by the so-called “Magnificent 7” has been fantastic if you owned those stocks. The reality is the great bulk of the S&P 500 is treading water for...
Published:
Here is a look at how shares of FuelCell Energy, Gilead Sciences, Starbucks and more have fared since their initial public offerings in 1992.
Published:
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and...
Published:
Monday's top analyst upgrades and downgrades included Adobe, Apple, Arch Capital, ChargePoint, CSX, Digital Ocean, First Solar, Gilead Sciences, Lucid, Shopify and Snowflake.
Published:
Private equity firms and institutions have been buying up top health care stocks like these seven for their strong total return potential and a degree of safety in what soon could be some very rough...
Published:
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange,...
Published:
When Nasdaq rebalances its Nasdaq 100 index, 7 top companies in the index will be upsized, and all are Buy rated across Wall Street.
Published:
The highest-yielding stocks in the Nasdaq offer a contrarian angle for the rest of 2023. They all have some solid defensive qualities, and they are offering among the best entry points seen in some...
Published:
Wednesday's top analyst upgrades and downgrades included Amgen, Canadian Pacific Kansas City, Carvana, Coinbase Global, Etsy, First Horizon, GE Healthcare Technologies, Gilead Sciences, Home Depot,...
Published:
Monday's top analyst upgrades and downgrades included CyberArk Software, Diageo, Dish Network, Electronic Arts, Fox, Gilead Sciences, Molson Coors Beverage, O’Reilly Automotive, PacWest Bancorp,...
Published:
Monday's top analyst upgrades and downgrades included Amazon.com, Bluebird Bio, Carnival, Fortinet, General Motors, Gilead Sciences, Hasbro, Hershey, Intel, International Paper, Masco, Mobileye...
Published: